Home-based tDCS for Huntington's Disease
This study is exploring whether transcranial direct current stimulation (tDCS) can help with cognitive and behavioral symptoms in people with Huntington's Disease (HD). tDCS is a device that applies a mild electrical current to the scalp. Researchers are looking for 16 participants, aged 18 to 85, who have a confirmed HD mutation or family history with typical HD symptoms like chorea, and are in early to moderate stages of the disease. You would receive a tDCS device to use at home for 30 minutes daily. The study will measure if participants meet the inclusion criteria, agree to join, and complete the first part of the study. The current status of the study is unclear.
- Study design
- This is an interventional study planning to enroll 16 participants. It compares active tDCS to a sham (inactive) tDCS device.
- What's involved
- You would use a tDCS device at home for 30 minutes daily, answer questions for study staff, and return for follow-up visits and cognitive tests. Caregivers will also be asked to answer questionnaires.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed at least through Day 13 of the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease
At a glance
Conditions
NCT06843252
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Texas Health Science Center at San Antonio
San Antonio, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Thiago Macedo e Cordeiro, MD, MSc · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center at San Antonio
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percentage of Participants that met Inclusion CriteriaBaseline
Percentage of participants screened that met Inclusion Criteria
- Percentage of Participants that Agreed to RandomizationBaseline
Percentage of eligible participants that were screened and met eligibility that agreed to be randomized.
- Completed period 1 of studyDay 13
Percentage of participants who completed first 2 weeks of treatment or sham
- Completed period 2 of studyDay 35
Percentage of participants that completed both the first period, the washout period and the second period of the study
- Completion of study to last visitDay 36 (or day 37)
Percentage of participants that completed study from randomization to tDCS/Sham crossed over to alternate treatment/sham and returned for final visit
- TDCS Acceptability ScaleDay 14 and Day 35
This Likert scale scores 10 items for user acceptability. Each item is scored from 0-10 giving. Some items have negative valence, in which lower scores indicate higher acceptability. An averaged of adjusted scores for all items is calculated to produce a global acceptability score ranging from 0 to 10. A higher score on the global score indicates better acceptability.
- tDCS Side Effects ScaleDay 8, 14, 29 and 35
This Likert scale includes 10 items scored from 0-10 for possible side effects. The first 9 items include a list of possible side effects and the last item is free field for the report of any additional side effects. Lower scores indicate less intensity of side effects. Scores will be reported for each individual item.